Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hemodynamic Evolution of Heart Failure from Hypertension: Lower Stroke Volume Index and Higher Heart Rate.

American journal of hypertension·2026
Same author

Impact of older donor age in kidney transplants in a biopsy-based observational study.

JCI insight·2026
Same author

Corrigendum to "Improving the histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants" [American Journal of Transplantation Volume 26, Issue 1, January 2026, Pages 117-130].

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Quantifying Change in Proteinuria After Acute Kidney Injury Among Patients With Chronic Kidney Disease: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.

Kidney medicine·2026
Same author

Optimizing Proteinuria Evaluation and Management after Acute Kidney Injury: Insights from the Chronic Renal Insufficiency Cohort Study.

Kidney360·2026
Same author

Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.

Journal of the American Society of Nephrology : JASN·2026

Related Experiment Video

Updated: May 29, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Angiotensin-converting enzyme inhibitors.

Joseph L Izzo1, Matthew R Weir

  • 1Erie County Medical Center and SUNY-Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA. jizzo@buffalo.edu

Journal of Clinical Hypertension (Greenwich, Conn.)
|September 8, 2011
PubMed
Summary

Angiotensin-converting enzyme inhibitors treat hypertension and other conditions like heart disease and kidney disease. Their effectiveness is influenced by sodium intake and individual responses, with benefits including renal protection.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Related Experiment Videos

Last Updated: May 29, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Pharmacology

Background:

  • Angiotensin-converting enzyme (ACE) inhibitors are crucial in managing hypertension.
  • ACE inhibitors target the renin-angiotensin system, influencing blood pressure and fluid balance.
  • Understanding ACE inhibitor mechanisms is key for optimizing patient outcomes.

Purpose of the Study:

  • To summarize key indications and considerations for ACE inhibitor therapy.
  • To highlight the biochemical action of ACE-1 (kininase II) on angiotensin and bradykinin.
  • To review factors affecting ACE inhibitor efficacy and safety.

Main Methods:

  • Review of established clinical guidelines and pharmacological principles.
  • Analysis of the biochemical role of ACE in the renin-angiotensin system.
  • Examination of clinical data regarding ACE inhibitor effects and adverse events.

Main Results:

  • ACE inhibitors are indicated for hypertension, high cardiovascular risk, post-myocardial infarction, dilated cardiomyopathy, and chronic kidney disease.
  • ACE-1 inactivates bradykinin and converts angiotensin I to angiotensin II; bypass pathways lack clinical significance in humans.
  • Dietary sodium impacts efficacy; salt restriction or diuretics enhance effects. Renal protective benefits are indicated by increased creatinine.
  • Contraindicated in pregnancy due to fetal toxicity. Side effects include cough, angioedema, hyperkalemia, and hypotension.

Conclusions:

  • ACE inhibitors offer broad therapeutic benefits beyond hypertension, particularly in cardiovascular and renal protection.
  • Careful patient selection and monitoring are essential to maximize benefits and minimize risks like hyperkalemia and hypotension.
  • Understanding individual responses and drug interactions, such as with sodium intake, is vital for effective ACE inhibitor therapy.